Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Tibco Expand Partnership to Support Clinical Research and Development Market

NEW YORK (GenomeWeb News) – Tibco Software said today that it has expanded its existing relationship with PerkinElmer so that its customers can benefit from PerkinElmer's investments in product and application development in the clinical research and development arena.

Under the terms of the expanded relationship, PerkinElmer will be the exclusive channel for the Tibco Spotfire software for use in clinical research and development applications, such as clinical trials to determine the safety and efficacy of medications, devices, diagnostic products, and treatment regimens; pre-approval and post-approval clinical trials; operational data on trial execution; safety risk monitoring; and adverse event tracking.

"Joining forces strengthens our vertical industry focus on pharmaceuticals and biotech, as well as many others, while giving TIBCO the means and capacity to focus on, and successfully invest in, expansion into other verticals and horizontals," according to Matt Quinn, Tibco's chief technology officer.

By pooling their resources, Tibco and PerkinElmer can together provide scientists with "a complete package of data generation, data management, plus data analysis and visualization, so they can better harness information for more informed insights and decisions in the clinical space," Mike Stapleton, PerkinElmer's general manager for informatics, added in the statement.